Filter Results:
(125)
Show Results For
- All HBS Web
(125)
- People (1)
- News (52)
- Research (57)
- Events (1)
- Multimedia (5)
- Faculty Publications (30)
Show Results For
- All HBS Web
(125)
- People (1)
- News (52)
- Research (57)
- Events (1)
- Multimedia (5)
- Faculty Publications (30)
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
The success of American Home Products reflects a unique path of learning. The company originated with the merger of several companies in related businesses. During the seventy years following its formation in 1926, the company's senior managers at their headquarters in... View Details
- 01 Aug 2006
- News
Big Pharma's Prognosis
- 14 Jul 2023
- Video
BiGS Idea: Rethinking Health Equity
- 26 Jan 2024
- Blog Post
HBS Alumna Fighting Cancer with a Novel Cell Therapy
originally planned to pursue a Ph.D., but instead spent four years at Catalent Pharma Solutions, a leading pharma/biotech contract manufacturing development organization. Surrounded by potential career paths in the industry, Zutshi... View Details
- September 2006 (Revised March 2010)
- Case
Teva Pharmaceutical Industries, Ltd
By: Tarun Khanna, Krishna G. Palepu and Claudine Deborah Madras
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's first and largest multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details
Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; India; Israel
Khanna, Tarun, Krishna G. Palepu, and Claudine Deborah Madras. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Case 707-441, September 2006. (Revised March 2010.)
- November 2016
- Case
Transformation at Eli Lilly & Co. (A)
By: William R. Kerr and Alexis Brownell
Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly sets out on a dramatic transformation process in 2009. The case considers how Lilly restructured the organization into business areas to aid better decision-making,... View Details
Keywords: Eli Lilly; Restructuring; R＆D; Transformation; Organizational Change and Adaptation; Organizational Structure; Pharmaceutical Industry; Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (A)." Harvard Business School Case 817-070, November 2016.
- 30 Mar 2023
- Video
Generating Breakthrough Therapies: Risk and Reward
- June 1998
- Supplement
MBA Integrative Exercise: Competition & Strategy, April 1998 , Video
By: Carin-Isabel Knoop
Daniel Vasella, President of Novartis AG, discusses the situation in Indonesia and his ideas of what Suharto should do in the spring of 1998. Drummond Paris, Regional Pharma Head Asia/Pacific, Novartis AG, discusses the opportunities for Novartis in Indonesia and also... View Details
Knoop, Carin-Isabel. "MBA Integrative Exercise: Competition & Strategy, April 1998 , Video." Harvard Business School Video Supplement 898-504, June 1998.
- 16 Mar 2021
- News
Robert Kaplan: The essence of long-term strategy
- 09 Jun 2015
- News
How Merck Is Trying to Keep Disrupters at Bay
- 30 Dec 2010
- News
Shrink It, Cure It
- 26 Apr 2019
- HBS Seminar
Maryaline Catillon, Harvard University
- November 2007
- Supplement
Teva Pharmaceutical Industries, Ltd.
By: Tarun Khanna and Krishna G. Palepu
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's largest and first multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details
Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; Israel; India
Khanna, Tarun, and Krishna G. Palepu. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Video Supplement 708-806, November 2007.
- 10 Dec 2018
- News
Did Free Pens Cause the Opioid Crisis?
- April 2025
- Case
Radical Transformation at Bayer: Dynamic Shared Ownership
By: Boris Groysberg and Gamze Yucaoglu
In 2023, Bill Anderson became CEO of Bayer AG, a 160-year-old life sciences giant looking to strengthen its pharma pipeline, manage debt, and cut through bureaucracy. His bold response: Dynamic Shared Ownership (DSO), a radical model replacing traditional hierarchies... View Details
Keywords: Human Resources; Business Strategy; Alignment; Innovation and Management; Organizational Structure; Agriculture and Agribusiness Industry; Pharmaceutical Industry
Groysberg, Boris, and Gamze Yucaoglu. "Radical Transformation at Bayer: Dynamic Shared Ownership." Harvard Business School Case 425-061, April 2025.
- January 2021
- Case
Takeda Pharmaceutical Company Limited (A)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn... View Details
Keywords: Pharmaceutical Companies; Pharmaceuticals; Biotech; Biotechnology; M＆A; Mergers ＆ Acquisitions; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Management; Global Strategy; Talent and Talent Management; Pharmaceutical Industry; Biotechnology Industry; Japan; Asia
Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (A)." Harvard Business School Case 721-373, January 2021.
- October 2023 (Revised May 2024)
- Case
Thermo Fisher Scientific: Foray into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details
Keywords: Mergers and Acquisitions; Customer Focus and Relationships; Corporate Strategy; Organizational Change and Adaptation; Biotechnology Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Thermo Fisher Scientific: Foray into Contract Research." Harvard Business School Case 824-073, October 2023. (Revised May 2024.)
- July 2023
- Case
HealthVerity: Real World Data and Evidence
By: Satish Tadikonda
Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma... View Details
Tadikonda, Satish. "HealthVerity: Real World Data and Evidence." Harvard Business School Case 824-019, July 2023.